Join
Live feed
·
PRReleasevia Quantisnow
Vera Therapeutics Inc. logo

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

ByQuantisnow·Wall Street's wire, on your screen.
VERA· Vera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VERA (Vera Therapeutics Inc.) and more on Quantisnow.